News

The company intends to submit an investigational new drug (IND) application for VT-1129 to the FDA in the first half of 2015. In preclinical trials, VT-1129 has been

The Phase III PIONEER I trial showed that Humira is effective in reducing common clinical signs and symptoms in moderate-to-severe HS, specifically the number of abscesses and inflammatory

The trial will assess the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults. About 90

As part of the deal, Asterias will complete development of the manufacturing process for AST-VAC2, after which CRT will produce the vaccine and conduct the Phase I/II clinical

The approval for the use of new indication follows a priority review of the supplemental new drug application (sNDA) that was based on results of the Phase III

Regenacyn is formulated from the company’s Microcyn Technology platform and is designed to address the underserved consumer scar management market. The company said that the hydrogel has been

The trial is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of G1T28-1 in healthy volunteers, who are currently being enrolled in the Netherlands. The company is conducting

OPT-UP is a U.S.-based, multicenter longitudinal clinical research study that will enroll 2500 people with MS and follow them for up to five years. The goals of the

A second report, a PhRMA-sponsored white paper by Boston Healthcare Associates, Inc. (BHA), "The Value of Innovation in HIV/AIDS Therapy," highlights the progress in HIV/AIDS treatment and its